The invention relates to a class of compounds of Formula I, including their pharmaceutically acceptable salts, solvates and/or prodrugs thereof, that prevent polymorphic cytochrome P450 mediated oxidative bioactivation, and the use of such compounds as therapeutics for the treatment, amelioration, and prevention of cardiovascular diseases.